FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987062912> ?p ?o ?g. }

• W1987062912 endingPage "1884" @default.
• W1987062912 startingPage "1877" @default.
• W1987062912 abstract "In Brief Purpose: To compare the concentration of unbound bevacizumab in the anterior chamber of patients with macular edema, who received a single intravitreal injection of two different dosages. Methods: This was a comparative, interventional case series. Twenty-nine nonvitrectomized eyes of 29 patients with significant lens opacities and concurrent macular edema were included in the study. All patients were treated by a single dose of intravitreal injection of bevacizumab 1.5 mg (Group A, n = 13) or 3.0 mg (Group B, n = 16). Subsequent phacoemulsification and aspiration of an aqueous humor samples were performed at various intervals (1–60 days). The axial length of the globe was measured using the IOLMaster to calculate the total volume and corresponding globe size–corrected half-time. The concentration of unbound bevacizumab was measured by enzyme-linked immunosorbent assay and pharmacokinetic parameters including half-time of elimination. Results: The mean peak concentration was observed in both groups on the first day after intravitreal bevacizumab injection. The mean concentration of unbound bevacizumab ranged in Group A from 17.5 μg/mL at baseline to 0.66 μg/mL at Day 57 and in Group B from 28.3 μg/mL at baseline to 0.00 μg/mL at 54 days. The axial lengths of all injected eyes were not significantly different between Group A (mean values, 23.026 mm, SD 1.21) and Group B (mean, 23.313 mm, SD 1.00; P = 0.31). Regression analysis determined elimination half-time values of 7.85 days (R2 = 0.75) in Group A and 11.67 days (R2 = 0.91) in Group B. Similar half-times were calculated for globe size–corrected concentrations with 8.21 days (R2 = 0.81) in Group A and 11.17 days (R2 = 0.88) in Group B. Conclusion: Single- and double-dose injections have similar pharmacokinetic characteristics in a first-order exponential decay function. The globe size–corrected concentration and half-time did not affect the calculated half-time in both groups. Doubled dosing induced a higher peak concentration at baseline, but the presumed extended biologic active concentration was no longer statistically significant after 6 weeks. The application of twice the dosage does not double the duration of its efficacy; it rather appears to extend the pharmacological duration by 1 half-time or approximately 8 days to 11 days. Doubling the dosage of intravitreal bevacizumab does not double the duration of its efficacy, but merely extends the duration by 1 half-time or approximately 8 days to 12 days and therefore seems to have no relevant clinical advantage over the single dosage." @default.
• W1987062912 created "2016-06-24" @default.
• W1987062912 creator A5016922490 @default.
• W1987062912 creator A5068725722 @default.
• W1987062912 creator A5089030421 @default.
• W1987062912 date "2011-10-01" @default.
• W1987062912 modified "2023-10-14" @default.
• W1987062912 title "INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5 mg VERSUS 3.0 mg OF BEVACIZUMAB IN HUMANS" @default.
• W1987062912 cites W1559170621 @default.
• W1987062912 cites W1985695422 @default.
• W1987062912 cites W1987590493 @default.
• W1987062912 cites W1988233478 @default.
• W1987062912 cites W1999611557 @default.
• W1987062912 cites W2002637725 @default.
• W1987062912 cites W2003645291 @default.
• W1987062912 cites W2011476120 @default.
• W1987062912 cites W2013306405 @default.
• W1987062912 cites W2014260690 @default.
• W1987062912 cites W2014311047 @default.
• W1987062912 cites W2015655380 @default.
• W1987062912 cites W2015843817 @default.
• W1987062912 cites W2019284100 @default.
• W1987062912 cites W2025630473 @default.
• W1987062912 cites W2042327890 @default.
• W1987062912 cites W2051193332 @default.
• W1987062912 cites W2058775052 @default.
• W1987062912 cites W2059826584 @default.
• W1987062912 cites W2060308011 @default.
• W1987062912 cites W2072011053 @default.
• W1987062912 cites W2072098479 @default.
• W1987062912 cites W2073888700 @default.
• W1987062912 cites W2073990613 @default.
• W1987062912 cites W2081273617 @default.
• W1987062912 cites W2084394581 @default.
• W1987062912 cites W2142693543 @default.
• W1987062912 cites W2151129590 @default.
• W1987062912 cites W2154770697 @default.
• W1987062912 cites W2163616867 @default.
• W1987062912 cites W2233259956 @default.
• W1987062912 doi "https://doi.org/10.1097/iae.0b013e318217373c" @default.
• W1987062912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21738089" @default.
• W1987062912 hasPublicationYear "2011" @default.
• W1987062912 type Work @default.
• W1987062912 sameAs 1987062912 @default.
• W1987062912 citedByCount "100" @default.
• W1987062912 countsByYear W19870629122012 @default.
• W1987062912 countsByYear W19870629122013 @default.
• W1987062912 countsByYear W19870629122014 @default.
• W1987062912 countsByYear W19870629122015 @default.
• W1987062912 countsByYear W19870629122016 @default.
• W1987062912 countsByYear W19870629122017 @default.
• W1987062912 countsByYear W19870629122018 @default.
• W1987062912 countsByYear W19870629122019 @default.
• W1987062912 countsByYear W19870629122020 @default.
• W1987062912 countsByYear W19870629122021 @default.
• W1987062912 countsByYear W19870629122022 @default.
• W1987062912 countsByYear W19870629122023 @default.
• W1987062912 crossrefType "journal-article" @default.
• W1987062912 hasAuthorship W1987062912A5016922490 @default.
• W1987062912 hasAuthorship W1987062912A5068725722 @default.
• W1987062912 hasAuthorship W1987062912A5089030421 @default.
• W1987062912 hasConcept C112705442 @default.
• W1987062912 hasConcept C118487528 @default.
• W1987062912 hasConcept C126322002 @default.
• W1987062912 hasConcept C141071460 @default.
• W1987062912 hasConcept C162156334 @default.
• W1987062912 hasConcept C2776694085 @default.
• W1987062912 hasConcept C2777802072 @default.
• W1987062912 hasConcept C2778257484 @default.
• W1987062912 hasConcept C2780347916 @default.
• W1987062912 hasConcept C2781104129 @default.
• W1987062912 hasConcept C2989005 @default.
• W1987062912 hasConcept C71924100 @default.
• W1987062912 hasConceptScore W1987062912C112705442 @default.
• W1987062912 hasConceptScore W1987062912C118487528 @default.
• W1987062912 hasConceptScore W1987062912C126322002 @default.
• W1987062912 hasConceptScore W1987062912C141071460 @default.
• W1987062912 hasConceptScore W1987062912C162156334 @default.
• W1987062912 hasConceptScore W1987062912C2776694085 @default.
• W1987062912 hasConceptScore W1987062912C2777802072 @default.
• W1987062912 hasConceptScore W1987062912C2778257484 @default.
• W1987062912 hasConceptScore W1987062912C2780347916 @default.
• W1987062912 hasConceptScore W1987062912C2781104129 @default.
• W1987062912 hasConceptScore W1987062912C2989005 @default.
• W1987062912 hasConceptScore W1987062912C71924100 @default.
• W1987062912 hasIssue "9" @default.
• W1987062912 hasLocation W19870629121 @default.
• W1987062912 hasLocation W19870629122 @default.
• W1987062912 hasOpenAccess W1987062912 @default.
• W1987062912 hasPrimaryLocation W19870629121 @default.
• W1987062912 hasRelatedWork W1240057634 @default.
• W1987062912 hasRelatedWork W2057502349 @default.
• W1987062912 hasRelatedWork W2347872078 @default.
• W1987062912 hasRelatedWork W2348622537 @default.
• W1987062912 hasRelatedWork W2350137300 @default.
• W1987062912 hasRelatedWork W2351322117 @default.
• W1987062912 hasRelatedWork W2412439554 @default.
• W1987062912 hasRelatedWork W2918920776 @default.

• next